Claims for Patent: 10,925,876

Summary for Patent: 10,925,876

Title:	Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
Abstract:	Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R, R, R, R, and Rare as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.
Inventor(s):	Berger Raphaelle, Dong Guizhen, Raghavan Subharekha, Yang Zhiqiang
Assignee:	Merck Sharp & Dohme Corp.
Application Number:	US16301936
Patent Claims:

Details for Patent 10,925,876

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	PULMOZYME	dornase alfa	Solution	103532	December 30, 1993		2037-05-12
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010		2037-05-12
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	October 21, 2013		2037-05-12
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	November 19, 2018		2037-05-12